Hale G - Search Results

1

Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.

Williams RJ, Clarke E, Blair A, Evely R, Hale G, Waldmann H, Brookes S, Pamphilon DH. Williams RJ, et al. Among authors: hale g. Cytotherapy. 2000;2(1):5-14. doi: 10.1080/146532400539008. Cytotherapy. 2000. PMID: 12042050

2

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.

Hale G, Waldmann H. Hale G, et al. J Hematother. 1994 Spring;3(1):15-31. doi: 10.1089/scd.1.1994.3.15. J Hematother. 1994. PMID: 7922004 Clinical Trial.

3

Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.

Hale G, Waldmann H. Hale G, et al. Bone Marrow Transplant. 1994 May;13(5):597-611. Bone Marrow Transplant. 1994. PMID: 8054913

4

Double T cell depletion of bone marrow using sequential positive and negative cell immunoaffinity or CD34+ cell selection followed by Campath-1M; effect on CD34+ cells and progenitor cell recoveries.

Clarke E, Potter MN, Hale G, Waldmann H, Lankester A, Cornish JM, Steward CG, Marks DI, Oakhill A, Pamphilon DH. Clarke E, et al. Among authors: hale g. Bone Marrow Transplant. 1998 Jul;22(2):117-24. doi: 10.1038/sj.bmt.1701296. Bone Marrow Transplant. 1998. PMID: 9707017

5

CAMPATH-1 antibodies in stem-cell transplantation.

Hale G, Cobbold S, Novitzky N, Bunjes D, Willemze R, Prentice HG, Milligan D, MacKinnon S, Waldmann H; CAMPATH Users. Hale G, et al. Cytotherapy. 2001;3(3):145-64. doi: 10.1080/146532401753173981. Cytotherapy. 2001. PMID: 12171722

6

Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy.

Lockwood CM, Thiru S, Isaacs JD, Hale G, Waldmann H. Lockwood CM, et al. Among authors: hale g. Lancet. 1993 Jun 26;341(8861):1620-2. doi: 10.1016/0140-6736(93)90759-a. Lancet. 1993. PMID: 8099991

7

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.

Hale G, Waldmann H. Hale G, et al. Bone Marrow Transplant. 1996 Mar;17(3):305-8. Bone Marrow Transplant. 1996. PMID: 8704678

8

Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users.

Hale G, Waldmann H. Hale G, et al. Blood. 1998 Apr 15;91(8):3079-83. Blood. 1998. PMID: 9531622 Free article.

9

Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart.

Cheetham GM, Hale G, Waldmann H, Bloomer AC. Cheetham GM, et al. Among authors: hale g. J Mol Biol. 1998 Nov 20;284(1):85-99. doi: 10.1006/jmbi.1998.2157. J Mol Biol. 1998. PMID: 9811544 Free article.

10

1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen.

James LC, Hale G, Waldmann H, Bloomer AC. James LC, et al. Among authors: hale g. J Mol Biol. 1999 Jun 4;289(2):293-301. doi: 10.1006/jmbi.1999.2750. J Mol Biol. 1999. PMID: 10366506

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

755 results

Search Page

Filters